DNA Tests in Detecting Disseminated Disease in Tumor, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01419509|
Recruitment Status : Completed
First Posted : August 18, 2011
Last Update Posted : May 17, 2016
RATIONALE: DNA analysis of tumor, blood, and bone marrow may help doctors predict if the disease has been disseminated.
PURPOSE: This research trial studies DNA tests in detecting disseminated disease in tumor, blood, and bone marrow samples from patients with rhabdomyosarcoma.
|Condition or disease||Intervention/treatment|
|Sarcoma||Genetic: DNA methylation analysis Genetic: microarray analysis Genetic: polymerase chain reaction Other: laboratory biomarker analysis|
- To establish a panel of hypermethylation assays for minimal disseminated disease analysis in rhabdomyosarcoma (RMS).
- To apply the hypermethylation assays to a series of bone marrow specimens from RMS patients.
OUTLINE: Archived tumor, bone marrow, and peripheral blood samples are analyzed for DNA hypermethylation by PCR-based assays and microarray assays. Results are then compared with each patient's clinical and pathological characteristics, and outcomes. Patterns of locus hypermethylation in tumor and paired bone marrow samples are also compared.
|Study Type :||Observational|
|Estimated Enrollment :||170 participants|
|Official Title:||DNA Methylation-based Assays for Detecting Disease Spread in Rhabdomyosarcoma|
|Study Start Date :||August 2011|
|Actual Primary Completion Date :||May 2016|
|Actual Study Completion Date :||May 2016|
- Panel of hypermethylation assays for minimal disseminated RMS
- Detection of RMS cells in bone marrow
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01419509
|Principal Investigator:||Stephen R. Master, MD||University of Pennsylvania|